The
report “Prostate Cancer Therapeutics
Market to 2019 – Rising Prevalence and Strong Uptake of Recent Approvals to
Drive Robust Growth to 2019″ by GBI
Research is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com
with Prostate Cancer Therapeutics Market
to 2019 – Rising Prevalence and Strong Uptake of Recent Approvals to Drive
Robust Growth to 2019 in subject line and your contact details to purchase
this report or get your questions answered.
The collection of ‘Cancer Therapeutics’ market research
reports has a new addition of “Prostate Cancer Therapeutics Market to 2019 – Rising
Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”
on RnRMarketResearch.com. The Pharmaceutical Report – “Prostate Cancer
Therapeutics Market to 2019 – Rising Prevalence and Strong Uptake of Recent
Approvals to Drive Robust Growth to 2019”. The recent approval of a number of
highly effective drugs, including Zytiga and Xtandi, has provided late-stage
patients with a number of options and increased survival times by a number of
months. These recent approvals are anticipated to generate strong revenues
during the forecast following increasing uptake by physicians as the treatment
algorithm shifts towards their first-line usage over Taxotere. Additionally, a
very large late-stage pipeline is anticipated to produce a number of new market
entrants which are superior to existing products. Overall, this is anticipated
to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019
at a CAGR of 10.1%.
Request a
sample copy of this report by GBI
Research @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=131133
.
Scope
- A
brief introduction to prostate cancer, including the disease’s
pathogenesis, risk factors, diagnosis, staging and treatment algorithms
for each stage.
- In-depth
analysis of drugs available for the treatment of prostate cancer,
including analyses of their safety, efficacy, treatment patterns and
strengths/weaknesses. Includes a heat map comparing the drugs in terms of
safety and efficacy.
- Comprehensive
review of the pipeline for prostate cancer therapies, including individual
analysis of a number of late-stage pipeline drugs that are likely to enter
the market in the forecast period. The pipeline is analyzed on the basis
of phase distribution, molecule types and molecular targets, program type.
- Additional
in-depth analysis of pipeline drug clinical trials by phase, molecule
type, trial size, trial duration and program failure rate analyses for
each molecule type and mechanism of action.
- Multi-scenario
forecast data of the market to 2019, taking into account how it will be
affected by the introduction of new drugs, the expiry of key patents on
current drugs and the changes in disease epidemiology across the key
developed markets including the US, Japan, Germany, the UK, France, Italy
and Spain.
- Discussion
of the drivers and barriers for market growth.
- Discussion
of the licensing and co-development deals landscape in prostate cancer,
Includes an analysis of licensing deals by stage of development, molecule
type and mechanism of action. Also includes an analysis of both licensing
and co-development deals by year and value and network maps of licensing
and co-development deals.
Complete report is available @ http://www.rnrmarketresearch.com/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-market-report.html. Read
more on “Prostate
Cancer Therapeutics Market to 2019 – Rising Prevalence and Strong Uptake of
Recent Approvals to Drive Robust Growth to 2019” report below.
Reasons to Buy
- Understand
the different levels of prostate cancer therapies, from early-stage
prostate cacner to metastatic and castrate-resistant prostate cancer.
- Understand
the vast scope and diversity of the pipeline, including which molecule
types and mechanisms of action are prominent.
- Observe
the trends in clinical trial duration and size amongst clinical Phases,
between molecule types and mechanisms of action, and use the clinical
trial failure rate analysis to assess the risk profiles of current and/or
future developmental programs for prostate cancer therapeutics.
- Assess
the potential clinical and commercial impact of current late-stage
pipeline molecules on the prostate cancer therapeutics market.
For
further information on “Prostate
Cancer Therapeutics Market to 2019 – Rising Prevalence and Strong Uptake of
Recent Approvals to Drive Robust Growth to 2019” report OR for any
other business research / market intelligence need on the ‘Cancer Therapeutics’
market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics
.), contact sales@rnrmarketresearch.com
/ Call +1 888 391 5441.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.